Ted Schwartz family gifts $15M to City of Hope to accelerate immunotherapy research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ted Schwartz, a cancer survivor, gifted $15M to City of Hope that will be used entirely to further accelerate immunotherapy research and treatment innovations, such as the CAR T-cell therapy that saved his life. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.